cross-conserved CD4+ T-Cell epitope vaccine (EpiVax)

N/A

Report date: 2025/01/26 16:28:38

Base Information

Drug Namecross-conserved CD4+ T-Cell epitope vaccine (EpiVax)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEpiVax Inc
China Registration ClassN/A

Develop Information

Active CompaniesEpiVax Inc
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A